3BNC117 and 10-1074

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Aarhus

Conditions

HIVHIV-1-infection

Phase 1

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

TerminatedNCT03571204

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2018-09-10End: 2021-03-29Updated: 2022-02-09

Phase 2

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

CompletedNCT03837756

University of AarhusHIV-1-infection

Start: 2019-05-06End: 2023-05-01Updated: 2023-05-23

Related Papers

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.

2023-09-1151 citations

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

2019-07-0927 citations